Nolpaza Control (pantoprazole) gastroresistive tablets 20 mg. №14

Description

Nolpaza Control composition
The active ingredient is pantoprazole sodium sesquihydrate 20 mg.

Release form
It is produced in the form of yellow-brown oval tablets, covered with an enteric coating.

Pharmacological properties
It is an antiulcer drug. The drug acts by inhibiting the proton pump of H + / K + -ATPase. When active molecules enter the tubular lumen of parietal cells, where the medium is acidic, they are oxidized, transforming into an active form. In this form, they bind the SH-groups of the H + / K + -ATPase, blocking (irreversibly) this enzyme. This disrupts the formation of hydrochloric acid (HCl), which is the main component of gastric juice.

Indications
Nolpaza Control is used in the treatment of gastroesophageal reflux disease, heartburn, sour regurgitation and pain when swallowing. In addition, the drug has proven its effectiveness in complex therapy in the eradication of Helicobacter pylori and gastric ulcer and intestinal ulcers caused by the intake of non-steroidal anti-inflammatory drugs. Nolpaza is indicated for the treatment of Zollinger-Ellison syndrome, as well as other pathological conditions that are associated with increased gastric secretion.

Contraindications
Cannot be used in the treatment of patients who suffer from dyspeptic disorders of neurotic etiology. Also, its use is unacceptable in case of hypersensitivity to the components of the drug.
When prescribing the drug, it is necessary to exclude the likelihood of the presence of malignant neoplasms in the patient, since the treatment can blur the clinical picture of the disease, which will not allow a timely diagnosis.

Children
It is not used in pediatrics.

Application during pregnancy and lactation
The experience of using the drug in the therapy of nursing and pregnant women is limited, and therefore, if it is necessary to use the drug during these periods, the necessary precautions should be taken.
The drug in the form of a lyophilisate is not used in the therapy of nursing and pregnant women.

Method of administration and dosage
Nolpaza Control is administered orally one hour before meals. The tablet is swallowed whole, without chewing, without crushing.
The standard dose for the symptomatic treatment of GERD gastroesophageal reflux disease is 20 mg / day for 2-4 weeks.
The standard dose for the prevention of gastric and duodenal ulcers caused by the use of non-selective non-steroidal anti-inflammatory drugs is 20 mg / day.
The standard dose for the treatment of reflux esophagitis is 40-80 mg / day, the course is 4 weeks. For the eradication of H. plori (in combination with antibiotics) – 40 mg 2 times a day, the course is 7-14 days.
The standard dose for the treatment of stomach ulcers is 40-80 mg / day, the course is 4 weeks.
The standard dose for the treatment of duodenal ulcers is 40-80 mg / day, the course is 4 weeks.
The standard dose for the treatment of Zollinger-Ellison syndrome and other hypersecretory conditions is 80-160 mg, the duration of use is limited to the period necessary to control acidity.

Overdose
Until recently, there were no cases of drug overdose.
When taking the drug in increased doses, the patient should flush the stomach and prescribe the intake of activated charcoal. In especially difficult cases, symptomatic therapy is recommended.

Side effects
When taking the drug, patients may complain of abdominal pain, stool disturbance, flatulence, dry mouth mucous membranes, nausea, vomiting, dizziness, visual impairment, peripheral edema and depression. In addition, patients with hypersensitivity to the drug may experience various allergic reactions, manifested by itching, skin rashes, hyperemia and anaphylactic shock.

Storage conditions and periods
Nolpaza Control should be stored in places that are out of the reach of children and protected from light. The duration of storage of the tablets – 5 years.